Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + peginterferon alfa-2a
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
**Capecitabine + peginterferon alfa-2a** is a combination drug regimen consisting of capecitabine, an oral fluoropyrimidine carbamate prodrug of 5-fluorouracil (5-FU), and peginterferon alfa-2a, a pegylated recombinant alpha interferon. Capecitabine is selectively activated within tumors to 5-FU, which inhibits thymidylate synthase and incorporates into RNA, leading to cytotoxicity in rapidly dividing cells. Peginterferon alfa-2a acts via the interferon alpha/beta receptor, activating the JAK/STAT pathway and stimulating innate immune responses with antiproliferative and immunomodulatory effects. The combination has been investigated primarily in advanced solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and brain metastases from breast cancer, with trials showing moderate but manageable toxicity and evidence of efficacy in subsets of patients[1][3][4].
- Other names
- capecitabine and pegylated interferon alfa-2acapecitabine + PEG-interferon alfa-2acapecitabine + peginterferon α-2a
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + peginterferon alfa-2a.